Recent news on Gemzar

Lilly to present new data on cancer drugs  -  May 23, 2007
Indianapolis Star,Lilly Oncology announced today it will unveil 76 studies, including data on its strong-seller cancer drugs Gemzar and Alimta, at a clinical oncology group's

Teva's generic Gemzar gets tentative OK  -  May 8, 2007
BusinessWeekEli Lilly sued the company in February 2006 to block Teva from making generic Gemzar. The filing blocked the FDA from granting Teva's petition for 30 months

Teva gets tentative FDA nod to market generic Gemzar  -  May 8, 2007
ReutersN: Quote, Profile, Research cancer treatment Gemzar for injection. Teva is facing a patent suit on this product and a final approval is expected upon the

More hopes for pancreatic cancer patients treated with combination ...  -  May 4, 2007
TopCancerNews.com,An early online publication of the Journal of Clinical Oncology states that the addition to the targeted agent Tarceva (erlotinib) to Gemzar (gemcitabine)

MethylGene Presents Preclinical Data for its Clinical Candidate ...  -  May 24, 2007
WM Experts (press release),...trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza® and Gemzar®.

Teva Receives Tentative FDA Approval For Generic Lilly Drug  -  May 9, 2007
Inside INdiana Business (press release),...s cancer treatment Gemzar. Israel-based Teva is currently involved in patent litigation concerning the product in US District Court for the Southern

Survival in pancreatic cancer improved  -  May 7, 2007
TopCancerNews.com,The Journal of Clinical Oncology, an online publication found that adding Tarceva(erlotinib) to Gemzar(gemcitabine) can improve the chances of survival.

FDA Tentatively Approves Gemcitabine Injection  -  May 9, 2007
Facts and Comparisons,The FDA has tentatively approved Teva Pharmaceutical Industries’ ANDA to market gemcitabine 200 mg base/vial for injection, the generic version of Gemzar by

HP Among Big Movers On Wall Street  -  May 8, 2007
MLive.com,...received tentative approval from the Food and Drug Administration to market its generic version of Eli Lilly & Co.'s indictable cancer treatment, Gemzar.

HP Among Big Movers On Wall Street  -  May 8, 2007
Ottawa Recorder,...from the Food and Drug Administration Food and Drug Administration to market its generic version of Eli Lilly & Co.‘s indictable cancer treatment, Gemzar.

Behavioral Insights Prove to be a Draw Not Only for Brands, But ...  -  May 22, 2007
PR Newswire (press release),Cobb's pharmaceutical brand experience includes Gemzar, Alimta, Humalog, Fuzeon, Cymbalta and Xigris. "Jamie is a proven creative leader and change agent,"

Behavioral Insights Prove to Be a Draw Not Only For Brands, But ...  -  May 22, 2007
Business Wire (press release),Cobb’s pharmaceutical brand experience includes Gemzar, Alimta, Humalog, Fuzeon, Cymbalta and Xigris. “Jamie is a proven creative leader and change agent,�

MethylGene Selects Histone Deacetylase Antifungal Clinical Candidate  -  May 17, 2007
PipelineReview.com (press release),...trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza® and Gemzar®.

Lung Cancer is the Third Most Common Malignant Disease and the ...  -  May 11, 2007
PharmaLive.com (press release),...drugs go off patent before 2012; Aventis' Taxotere (docetaxel), Bristol-Myers Squibb's Paraplatin (carboplatin) and Eli Lilly's Gemzar (gemcitabine).

Pharma cos unfazed by US regulatory hurdles  -  May 4, 2007
Economic Times,Eli Lilly and Company has sued Sun Pharmaceuticals to stop the Indian company from marketing the generic version of its blockbuster cancer drug Gemzar.

Pharmexa starts pivotal phase III trial in the United States  -  May 4, 2007
PipelineReview.com (press release),Brief description of the trial In the PrimoVax trial, GV1001 will be tested side by side with the current standard treatment gemcitabine (Gemzar(R)),

Gemzar® plus a Platinum Compound is Standard of Care for Biliary ...  -  Apr 3, 2007
Cancer Consultants (press release),On the basis of a review of the literature researchers from Germany have concluded that Gemzar (gemcitabine) plus a platinum compound is the current

Lilly Oncology Focused on Pharmacogenomics at AACR Annual Meeting  -  Apr 17, 2007
Drug Newswire (press release),GEMZAR, which celebrated its 10th anniversary as a marketed product for patients in the United States last year, forms the basis of two trials being

ImClone Systems: Erbitux takes a knock  -  Apr 11, 2007
Pharmaceutical Business ReviewImClone Systems' and Bristol-Myers Squibb's Erbitux in combination with Eli Lilly's Gemzar in patients with locally advanced unresectable or metastatic

ImClone slides as pancreatic cancer trial misses mark  -  Apr 12, 2007
BiopharmaReporter.com,These trials include: IMCL-055, looking at Erbitux/Avastin plus Gemzar; ECOG 8200, which is investigating Erbitux use alongside chemotherapy with irinotecan

Eli Lilly sues Sun Pharma over patent  -  Apr 1, 2007
Business Standard,Gemzar, a commonly used cancer drug to treat non-small cell lung cancer, pancreatic, bladder and breast cancer, is one among the top selling drugs of Eli

Erbitux Fails to Prolong Life  -  Apr 10, 2007
Wall Street Journal (subscription),...s Gemzar with Gemzar alone in 700 people with pancreatic cancer that is either locally advanced and untreatable by surgery, or metastatic, which means it

Eli Lilly's profits take a tumble  -  Apr 17, 2007
Pharma Times (subscription),This growth was fuelled by strong sales of the company's depression drug Cymbalta (duloxetine) and cancer treatments Gemzar (gemcitabine) and Alimta

Setback For Pancreatic Cancer Drug  -  Apr 12, 2007
Post Chronicle...s Gemzar, with Gemzar alone, in a group of 700 patients with pancreatic cancer that was either untreatable with surgery or that had spread to other parts of

Lilly beats Street on Cymbalta demand  -  Apr 16, 2007
Canada.com,Cancer treatments Gemzar and Alimta, schizophrenia drug Zyprexa and impotence treatment Cialis all showed sales gains.

Lilly profit falls 39 percent  -  Apr 16, 2007
CNNMoney.comIndianapolis-based Lilly said sales jumped 14 percent to $4.23 billion, fueled by higher sales of depression drug Cymbalta and cancer treatments Gemzar and

Study Reviews Chemotherapy for Advanced Biliary Tract Cancer  -  Apr 4, 2007
Cancer Consultants (press release),According to the results of a combined analysis of previously published studies, chemotherapy with a combination of Gemzar® (gemcitabine) and a platinum

Certain genes make chemotherapy drugs more potent at lower doses  -  Apr 16, 2007
TopCancerNews.com,Two other drugs -- Navelbine and Gemzar -- were tested on six of the Taxol-sensitive genes. The genes did not respond to these drugs.

Scientists discover chemotherapy sensitive genes  -  Apr 12, 2007
Pharmaceutical Business Review...with Taxol and tried the same test using the chemotherapy drugs Navelbine and Gemzar, but the results were not as dramatic as those seen for Taxol.

"Cancer Better Be Scared Of Me"  -  Mar 29, 2007
CBS News,Her oncologist at UCLA put her on a more aggressive chemotherapy; Gemzar and 5fu. The drugs made her sick and she lost more weight and more hair.

ImClone's Erbitux Fails Pancreatic Cancer Trial  -  Apr 10, 2007
Reuters.uk,N: Quote, Profile , Research) chemotherapy Gemzar, or gemcitabine, with gemcitabine alone in patients whose cancer could not be surgically treated or had

ImClone stock drops on Erbitux-chemo results  -  Apr 10, 2007
Crain's New York Business,...s Gemzar chemo drug. Erbitux is currently approved to treat colorectal cancer as well as head and neck cancer. Pancreatic cancer is the most aggressive and

'An end to struggle, and closure'  -  Apr 8, 2007
Philadelphia Inquirer,But here I am five years later, feeling like a trapeze artist as I grasp the rung of each successive treatment - chemo drugs (Taxol and Gemzar),

Cancer, Up Close And Personal  -  Mar 28, 2007
CBS News,And she is, thanks to new drugs called Gemzar and 5 FU. "I'd like to be a walking miracle. I'd like to feel that way, but I don't," Ronnau says.

Lilly Reports Strong First-Quarter Results; Raises Full-Year Sales ...  -  Apr 16, 2007
Genetic Engineering News (press release),Gemzar had sales totaling $376.9 million for the first quarter, an increase of 11 percent from the first quarter of 2006. Sales in the US increased 9

AstraZeneca to Pay $15.6B for MedImmune  -  Apr 23, 2007
Smartmoney.comAlthough not currently in the vaccine business, Lilly does market the cancer drugs Gemzar and Alimta. MedImmune, which generated $1.3 billion in revenue in

Lilly Reports Strong First-Quarter Results; Raises Full-Year Sales ...  -  Apr 16, 2007
PR Newswire (press release),Gemzar Gemzar had sales totaling $376.9 million for the first quarter, an increase of 11 percent from the first quarter of 2006. Sales in the US increased 9

MethylGene to Present at BioFinance 2007  -  Apr 23, 2007
Genetic Engineering News (press release),...trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza(R) and Gemzar(R).

MethylGene to Present at BioFinance 2007  -  Apr 23, 2007
Market Wire (press release)...trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza® and Gemzar®.

MethylGene to Present at BioFinance 2007  -  Apr 23, 2007
CCNMatthews (press release),...trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza ® and Gemzar ® .

Pharma Sector: Few Newsmakers Of The Week - Merck, Pfizer, Mylan ...  -  Apr 14, 2007
Trading Markets,...s chemotherapy Gemzar or Gemzar alone. Erbitux is the only marketed product for Imclone and the company has been searching for additional indications for

Biotech Day In Review: Entereg from GSK and Adolor Fails Test  -  Apr 10, 2007
Seeking Alpha,Erbitux was given together with Gemzar from Lilly (LLY) to patients who had unresectable or metastatic pancreatic cancer, but the addition of Erbitux did

Lilly profit falls 39 percent  -  Apr 16, 2007
CNNMoney.comCompany sales jumped 14 percent to $4.23 billion, above the Reuters Estimates forecast of $4.11 billion, as cancer treatments Gemzar and Alimta,

Analysis: Mixed views on Lilly's strong Q1  -  Apr 16, 2007
United Press InternationalGemzar sales hit $377 million while Alimta sales totaled $188 million. Byetta sales came in at $72 million. Based on the quarter's performance, Lilly raised

Eli Lilly Lifts Its Forecast  -  Apr 16, 2007
Briefing.com,Both Gemzar and Humalog grew 11% to $376 and $339 million, respectively. Revenue from Byetta, an injectable Type-2 diabetes treatment, rose 7% to $147

Cyclacel Pharmaceuticals CEO Speaks About His Company  -  Apr 16, 2007
Seeking Alpha,It also works by a different mechanism than the best known nucleoside analog, a drug called gemcitabine or Gemzar, which is generating annual sales of about

Massive Gene Screening Points Way To More Effective Chemotherapy  -  Apr 15, 2007
Medical News Today (press release),...test using the chemotherapy drugs vinorelbine (Navelbine) and gemcitabine (Gemzar), but the results were not as dramatic as those seen for paclitaxel.

Study uncovers genes which affect chemotherapy impact  -  Apr 13, 2007
Cancer Research UK - News & Resources,Postdoctoral researcher Dr Angelique Whitehurst explained that tests involving other chemotherapy drugs, vinorelbine (Navelbine) and gemcitabine (Gemzar),

Genes May Boost Lung Cancer Chemo  -  Apr 11, 2007
WebMDWhite's team also tested six Taxol-sensitive genes with two other chemotherapy drugs, Navelbine and Gemzar. The Taxol-sensitive genes weren't very sensitive

Windfall for cos eyeing US oncology market  -  Apr 10, 2007
Economic Times,Gemcitabine, marketed by US drug giant Eli Lilly under the brand name Gemzar, will lose market exclusivity in 2009 in the US, while Roche Laboratories’

Erbitux Misses In Pancreatic Cancer, Dropping ImClone  -  Apr 11, 2007
BioWorld Online,The open-label, randomized trial, conducted by the Southwest Oncology Group, compared Erbitux and the chemotherapy gemcitabine (Gemzar, Eli Lilly & Co.

ImClone's Erbitux flunks new cancer trial  -  Apr 10, 2007
CNNMoney.com...s chemotherapy Gemzar, or gemcitabine, with gemcitabine alone in patients whose cancer could not be surgically treated or had spread to other parts of the

ImClone shares suffer as Erbitux pancreatic cancer trial fails  -  Apr 11, 2007
Pharma Times (subscription),ImClone and partner Bristol-Myers Squibb announced that a Phase III study of Erbitux (cetuximab) plus a standard chemotherapy, Eli Lilly's Gemzar

ImClone: Erbitux Falls Short on Pancreas  -  Apr 10, 2007
Forbes,...s Gemzar chemo drug. Pancreatic cancer is the most aggressive and difficult to treat of all cancers. About 33700 patients will be diagnosed and about 32000

ImClone's Erbitux Fails Pancreatic Cancer Study  -  Apr 11, 2007
Seeking Alpha,The trial was intended to demonstrate that Erbitux, when used in combination with Eli Lilly's Gemzar chemotherapy drug, would improve overall survival rates

Erbitux fails pancreatic cancer trial  -  Apr 10, 2007
WIS,N) chemotherapy Gemzar, or gemcitabine, with gemcitabine alone in patients whose cancer could not be surgically treated or had spread to other parts of the

Lilly takes on three rivals in Gemzar patent fight  -  27 Mar 2007
The Herald-Times (subscription),The Indianapolis drug maker has filed three lawsuits against companies that want to make generic versions of Gemzar, an injectible chemotherapy that treats

Eli Lilly to expand in Singapore  -  27 Mar 2007
International Herald Tribune,Sales of Gemzar, for cancer, reached $371 million, according to data compiled by Bloomberg. The city-state wants to be a health-care hub by exploiting its

Weekly Taxol®, Eloxatin®, Leucovorin and 5-FU Promising for ...  -  Mar 23, 2007
Cancer Consultants (press release),Treatment for advanced or metastatic disease typically consists of single-agent Gemzar or Gemzar in combination with other agents.

Study Evaluates Chemotherapy with Gemzar® and Paraplatin® in Lung ...  -  Mar 7, 2007
Cancer Consultants (press release),According to the results of a Phase II clinical trial published in the Journal of Thoracic Oncology, the combination of Gemzar® (gemcitabine) and

Eli Lilly lays out expansion plans for Japanese unit  -  Mar 20, 2007
Pharma Times (subscription),Sales of the cancer drug Gemzar (gemcitabine) generated 13 billion yen, 18% up on the previous year, notes Bloomberg. As part of its global restructuring,

New Breast Cancer Drug Combination Proves More Effective  -  Mar 16, 2007
TopCancerNews.com,One group of women was treated with Gemzar (gemcitabine) and Navelbine (vinorelbine), the other group was treated with Navelbine alone.

Avastin® plus Chemotherapy Improves Progression-free Survival with ...  -  Feb 27, 2007
Cancer Consultants (press release),Patients were divided into the following three treatment groups: higher doses of Avastin plus Gemzar/Platinol; moderate doses of Avastin plus

Biotech Day in Review: Biotech Takes a 3% Hit  -  Feb 27, 2007
Seeking Alpha,The trial tested the drug in patients with metastatic pancreatic cancer who had failed an earlier round of Gemzar from Lilly (LLY).

Threshold Over the Edge  -  Feb 28, 2007
Motley FoolLilly's (NYSE: LLY) Gemzar in treating pancreatic cancer, but with no comparator standard of care arm, the trial's results are not easily interpretable.

MethylGene Reports Year-End 2006 Financial Results  -  Mar 8, 2007
SYS-CON Media,A Phase I/II trial (Trial 006) with MGCD0103 in combination with Gemzar® in pancreatic cancer patients was also initiated;

British doctors to start new phase III trial with Pharmexa's GV1001  -  Mar 16, 2007
PipelineReview.com (press release),In the TeloVac study, GV1001 will be tested together with a combination of the chemotherapy compounds gemcitabine (Gemzar®) and capecitabine (Xeloda®).

British Doctors to Start New Phase III Trial with Pharmexa's GV1001  -  Mar 15, 2007
PharmaLive.com (press release),Brief details on the trial In the TeloVac study, GV1001 will be tested together with a combination of the chemotherapy compounds gemcitabine (Gemzar®) and

MethylGene to Present at Cambridge Healthtech Institute's ...  -  Mar 15, 2007
SYS-CON Media,...trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza® and Gemzar®.

Rough Week for Biotech  -  Mar 5, 2007
Seeking Alpha,During the week, the company reported that its lead drug, glufosfamide, failed to provide a statistically significant advantage when added to Gemzar from

Does industry sponsorship influence drug trial results?  -  Mar 2, 2007
DrugResearcher.com,A spokesperson for Eli Lilly, which markets breast cancer drug Gemzar (gemcitabine), said he was unable to comment, as he hadn't seen the report.

Point Therapeutics Provides Clinical Update  -  Mar 2, 2007
PipelineReview.com (press release),In early January of 2007, the Company provided preliminary results from their open-label Phase 2 trial of talabostat plus gemcitabine (Gemzar(R): Eli Lilly)

Biotech Day In Review: Amgen Hit with SEC Investigation  -  Mar 1, 2007
Seeking Alpha,Talabostat was given as an adjunct to Gemzar from Lilly (LLY) to patients with Stage IV pancreatic cancer who had not previously been treated.

Threshold Pharma Down on Trial Results  -  Feb 27, 2007
Houston Chronicle,...s Gemzar, a standard chemotherapy drug for pancreatic cancer. Threshold intends to persevere with additional testing of the drug. The company is currently

MethylGene Year-End Results Conference Call Notice  -  Feb 28, 2007
Genetic Engineering News (press release),...trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza(R) and Gemzar(R).

MethylGene Year-End Results Conference Call Notice  -  Feb 28, 2007
CCNMatthews (press release),...trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza ® and Gemzar ® .

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional